SurModics, Roche deal

Roche and its Genentech Inc. unit received an exclusive license from SurModics to use its biodegradable microparticles drug delivery system to develop and commercialize sustained delivery formulations of Lucentis ranibizumab and other ophthalmic drugs. SurModics will receive $3.5 million up front and is eligible for up to $200 million in milestones, plus royalties. SurModics also is eligible for R&D fees. ...